ClinicalTrials.gg
CompletedNCT04614337OraGrowtH210Updated Jun 17, 2026Results posted

Phase 2 Study of LUM-201 in Children With Growth Hormone Deficiency (OraGrowtH210 Trial)

A Phase 2 interventional study of LUM-201 and rhGH Norditropin® pen (34 µg/kg) in Growth Hormone Deficiency, sponsored by Lumos Pharma. Completed at 43 sites in 6 countries. Open to participants aged 3 Years to 12 Years. Per ClinicalTrials.gov, last updated 2026-06-17.

Sponsored by Lumos Pharma · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
3 Years to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 89 studies in Dwarfism, Pituitary with a site in United States — 11 open to participants now, 12 under way, 3 of them phase 3. Dwarfism, Pituitary · United States.

Enrollment
17th of 66
104 · median 49
Started
2020
with 1 other
Phase 2
15 of 89
3 open now
Registered
75th of 89
by date
Lead sponsor
4 of 89
Lumos Pharma

Among the 89 studies in Dwarfism, Pituitary with a site in United States, this one is the 17th largest by enrollment of the 66 interventional ones that give a count, is one of 2 that started in 2020, is one of 15 in phase 2, and was the 75th registered.

Dwarfism, Pituitary

252 studies on the registry are indexed under Dwarfism, Pituitary; 30 are open to participants now.

Browse Dwarfism, Pituitary studies →

Open to participants now

11 of the 89 studies in Dwarfism, Pituitary with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 20 Dwarfism, Pituitary studies recruiting now, 5 (25%) set no upper age limit and 12 (60%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: 3 Years to 12 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 89 studies in Dwarfism, Pituitary with a site in United States, or all of them as a file.
02

Study summary

This is a multi-national trial. The goals of the trial are to study LUM-201 as a possible treatment for Pediatric Growth Hormone Deficiency (PGHD) and investigate a predictive enrichment marker (PEM) strategy to select subjects likely to respond to therapy with LUM-201.

Read the detailed description

This trial will have one screening visit with tests to assess if subjects are eligible to start study therapy. Once subjects have completed screening, and if they are determined to be eligible, they will be randomized to receive one of three oral daily doses of LUM-201 or daily injections of recombinant human growth hormone (rhGH). All subjects will have an equal chance of being placed in any of the four groups.

The trial consists of up to 24 months of treatment. After screening, subjects will return to the clinic for 6 (subjects placed in rhGH group) or 10 visits (subjects placed in LUM-201 group). During several of these clinic visits, subjects will have a physical exam, blood, and urine collections. There will also be 3 phone calls with study staff that will take place between the clinic visits.

03

Conditions studied

  • Growth Hormone Deficiency

Browse trials for

Keywords

  • GHD
  • Pediatric Growth Hormone Deficiency
  • LUM-201
  • Growth hormone secretagogue
  • Height
  • Catch-up growth
  • PEM
  • Oral
  • Predictive Enrichment Marker
04

Who can participate

Ages eligible
3 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have an established diagnosis of idiopathic PGHD as determined by standard diagnostic criteria. Eligible subjects must be naïve-to-treatment and be prepubertal.
  • Morning cortisol ≥ 7 µg/dL or stimulated cortisol ≥ 14 µg/dL.
  • At Screening, be ≥ 3.0 years and ≤ 11.0 years for girls and ≤ 12.0 years for boys.
  • Have HT-SDS ≤ -2.0 or HT-SDS ≥ 2 SD below mean parental HT-SDS.
  • Have a baseline height velocity \< 5.5 cm/year based on at least 6 months of growth.
  • Have a bone age delayed by ≥ 6 months with respect to chronological age.
  • Have prepubertal status as evidenced by Tanner Stage I breast development in girls and testicular volume \< 4.0 mL in boys.
  • In girls, have genetic testing results to rule out Turner syndrome. If SHOX genetic testing results are available, they need to be negative.
  • Have normal thyroid function. Subjects diagnosed with hypothyroidism must have documented successful treatment for at least 30 days prior to Day 1.

Exclusion criteria

Exclusion Criteria:

  • Any medical or genetic condition which, in the opinion of the Investigator or Medical Monitor (MM), can be an independent cause of short stature and/or limit the response to exogenous growth factor treatment. (Examples: diabetes, idiopathic short stature).
  • A medical or genetic condition that, in the opinion of the Investigator and/or MM, adds unwarranted risk to use of LUM-201 or rhGH.
  • Use of any medication that, in the opinion of the Investigator and/or MM, can independently cause short stature or limit the response to exogenous growth factors (Example: ).
  • Evidence or history of an intracranial mass (e.g., pituitary tumor, craniopharyngioma).
  • Suspicion of absent pituitary function as evidenced by a maximal stimulated GH ≤ 3 ng/mL on two prior standard of care GH stimulation tests, or pituitary deficiencies beyond GH and thyroid function.
  • Malnutrition as evidenced by medical history or a body weight \< 3rdth percentile for current height.
  • > 95th percentile.
  • Gestational age-adjusted birth weight \< 5th percentile (small for gestational age).
  • History of spinal, cranial, or total body irradiation.
  • Treatment with medications known to act as moderate or strong inhibitors or strong inducers of /4, or with medications known to act as strong inhibitors of P-glycoprotein (P-gp) or potent substrates of P-gp or Multidrug and toxin extrusion protein 1 (MATE1).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
104 participants (actual)

Study arms

  • Experimental
    LUM-201 (0.8 mg/kg/day)

    Drug: LUM-201

  • Experimental
    LUM-201 (1.6 mg/kg/day)

    Drug: LUM-201

  • Experimental
    LUM-201 (3.2 mg/kg/day)

    Drug: LUM-201

  • Active comparator
    rhGH (34 µg/kg/day)

    Drug: rhGH Norditropin® pen (34 µg/kg)

Interventions

  • Administered orally once daily

  • DrugrhGH Norditropin® pen (34 µg/kg)

    Administered subcutaneously (s.c., under the skin) once daily.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a Positive Growth Response From Day 1 to Month 6 (AHV >= 6.85 cm/yr)

    Annualized height velocity (AHV); Height is measured in triplicate, by a calibrated stadiometer and taking the mean value AVH equation is (h2-h1/t2-t1)\*365.25; h1 = height measured at day 1 h2 = height measured at month 6 t1 = day 1 t2 = month 6

    Time frame: Day 1 to Month 6

  2. AHV After 6 Months on LUM-201 Compared to rhGH

    Annualized height velocity to be measured.

    Time frame: Day 1 to Month 6

Secondary outcomes

  1. Percentage of Participants With a Positive Result on Both PEM Tests (at Screening and on Day 1)

    PEM Test Reproducibility Safety Population

    Time frame: Screening to Day 1

  2. Change in Height Standard Deviation Score (SDS)

    Full Analysis Set Population month 6

    Time frame: Day 1 to Month 6

  3. Change in Height Standard Deviation Score (SDS)

    Full Analysis Set Population month 12

    Time frame: Day 1 to Month 12

  4. Change in Weight From Baseline

    Change in Weight from baseline

    Time frame: Day 1 to Month 6

  5. Change in Weight From Baseline

    Change in Weight from baseline

    Time frame: Day 1 to Month 12

  6. Change in Weight SDS

    Change in Weight-SDS (Standard Deviation Score)

    Time frame: Day 1 to Month 6

  7. Change in Weight SDS

    Change in Weight-SDS (Standard Deviation Score)

    Time frame: Day 1 to Month 12

  8. Change in Body Mass Index (BMI)

    Change in BMI from baseline

    Time frame: Day 1 to Month 6

  9. Change in BMI

    Change in BMI (Body Mass Index) from baseline

    Time frame: Day 1 to Month 12

  10. Change in BMI SDS

    Change in BMI SDS

    Time frame: Day 1 to Month 6

  11. Change in BMI SDS

    Change in BMI SDS This is not a Z-Score analysis. Standard deviation score of 0 is the population mean for the age/sex. Normal range is typically -2 to +2 SDS. A positive score is an improvement and a negative score a decrease.

    Time frame: Day 1 to Month 12

  12. Bone Age

    Change in bone age, measured by X-ray of left hand and wrist using Greulich \& Pyle atlas

    Time frame: Day 1 to Month 6

  13. Bone Age

    Change in bone age, measured by X-ray of left hand and wrist using Greulich \& Pyle atlas

    Time frame: Day 1 to Month 18

  14. Pharmacokinetics of LUM-201

    Serum concentrations at 30 minutes (Cmax/Steady State)

    Time frame: Day 1 to Month 6

  15. Growth Hormone (GH) Concentration on Maintenance Treatment

    Serum GH concentration

    Time frame: Month 6

  16. Growth Hormone (GH) Concentration on Maintenance Treatment

    Serum GH concentration

    Time frame: Month 12

  17. Insulin-like Growth Factor 1 SDS

    Serum concentrations of insulin-like growth factor 1 This is not a Z-Score analysis. Standard deviation score of 0 is the population mean for the age/sex. Normal range is typically -2 to +2 SDS. A positive score is an improvement and a negative score a decrease.

    Time frame: Month 6

  18. Insulin-like Growth Factor 1 SDS

    Serum concentrations of insulin-like growth factor 1 This is not a Z-Score analysis. Standard deviation score of 0 is the population mean for the age/sex. Normal range is typically -2 to +2 SDS. A positive score is an improvement and a negative score a decrease.

    Time frame: Month 12

07

Results

Posted Jun 17, 2026

Participant flow

Period 1: Qualification Phase
Participant flow — Period 1: Qualification Phase
MilestonePredictive Enrichment Marker (PEM) Dose LUM-201 (0.8 mg/kg/Day)LUM-201 (0.8 mg/kg/Day)LUM-201 (1.6 mg/kg/Day)LUM-201 (3.2 mg/kg/Day)rhGH (34 µg/kg/Day)
Started1040000
Completed820000
Not completed220000
Withdrew: Lack of efficacy220000
Period 2: Randomization Phase
Participant flow — Period 2: Randomization Phase
MilestonePredictive Enrichment Marker (PEM) Dose LUM-201 (0.8 mg/kg/Day)LUM-201 (0.8 mg/kg/Day)LUM-201 (1.6 mg/kg/Day)LUM-201 (3.2 mg/kg/Day)rhGH (34 µg/kg/Day)
Started018222220
Completed056818
Not completed01316142
Withdrew: Withdrawal by subject01202
Withdrew: Failed annualized height velocity criteria, or transitioned to extension study early.01213140
Withdrew: Physician decision00100

Outcome measures

PrimaryPercentage of Participants With a Positive Growth Response From Day 1 to Month 6 (AHV >= 6.85 cm/yr)

Annualized height velocity (AHV); Height is measured in triplicate, by a calibrated stadiometer and taking the mean value AVH equation is (h2-h1/t2-t1)\*365.25; h1 = height measured at day 1 h2 = height measured at month 6 t1 = day 1 t2 = month 6

Time frame:
Day 1 to Month 6
Reported as:
Number · percentage of participants
Percentage of Participants With a Positive Growth Response From Day 1 to Month 6 (AHV >= 6.85 cm/yr)
percentage of participantsLUM-201 (0.8 mg/kg/Day)LUM-201 (1.6 mg/kg/Day)LUM-201 (3.2 mg/kg/Day)Recombinant Human Growth Hormone (rhGH) (34 µg/kg/Day)
Percentage of Participants With a Positive Growth Response From Day 1 to Month 6 (AHV >= 6.85 cm/yr)44.472.772.7100
PrimaryAHV After 6 Months on LUM-201 Compared to rhGH

Annualized height velocity to be measured.

Time frame:
Day 1 to Month 6
Reported as:
Mean · centimeters per year
AHV After 6 Months on LUM-201 Compared to rhGH
centimeters per yearLUM-201 (0.8 mg/kg/Day)LUM-201 (1.6 mg/kg/Day)LUM-201 (3.2 mg/kg/Day)rhGH (34 µg/kg/Day)
AHV After 6 Months on LUM-201 Compared to rhGH6.7575 ± 1.301418.2135 ± 1.880927.7342 ± 1.7970610.5739 ± 2.04380
SecondaryPercentage of Participants With a Positive Result on Both PEM Tests (at Screening and on Day 1)

PEM Test Reproducibility Safety Population

Time frame:
Screening to Day 1
Reported as:
Number · percentage of participants
Percentage of Participants With a Positive Result on Both PEM Tests (at Screening and on Day 1)
percentage of participantsSubjects With Positive Agreement on PEM Tests
Percentage of Participants With a Positive Result on Both PEM Tests (at Screening and on Day 1)100 (95.4 to 100)
SecondaryChange in Height Standard Deviation Score (SDS)

Full Analysis Set Population month 6

Time frame:
Day 1 to Month 6
Reported as:
Mean · Standard Deviation Score
Change in Height Standard Deviation Score (SDS)
Standard Deviation ScoreLUM-201 (0.8 mg/kg/Day)LUM-201 (1.6 mg/kg/Day)LUM-201 (3.2 mg/kg/Day)rhGH (34 µg/kg/Day)
Change in Height Standard Deviation Score (SDS)0.108 ± 0.12300.238 ± 0.17670.215 ± 0.17160.444 ± 0.1810
SecondaryChange in Height Standard Deviation Score (SDS)

Full Analysis Set Population month 12

Time frame:
Day 1 to Month 12
Reported as:
Mean · Standard Deviation Score
Change in Height Standard Deviation Score (SDS)
Standard Deviation ScoreLUM-201 (0.8 mg/kg/Day)LUM-201 (1.6 mg/kg/Day)LUM-201 (3.2 mg/kg/Day)rhGH (34 µg/kg/Day)
Change in Height Standard Deviation Score (SDS)0.207 ± 0.23590.370 ± 0.27860.369 ± 0.25140.732 ± 0.2424
SecondaryChange in Weight From Baseline

Change in Weight from baseline

Time frame:
Day 1 to Month 6
Reported as:
Mean · kg
Change in Weight From Baseline
kgLUM-201 (0.8 mg/kg/Day)LUM-201 (1.6 mg/kg/Day)LUM-201 (3.2 mg/kg/Day)rhGH (34 µg/kg/Day)
Change in Weight From Baseline2.392 ± 1.38592.680 ± 1.27102.530 ± 0.71331.737 ± 0.6940
SecondaryChange in Weight From Baseline

Change in Weight from baseline

Time frame:
Day 1 to Month 12
Reported as:
Mean · kg
Change in Weight From Baseline
kgLUM-201 (0.8 mg/kg/Day)LUM-201 (1.6 mg/kg/Day)LUM-201 (3.2 mg/kg/Day)rhGH (34 µg/kg/Day)
Change in Weight From Baseline4.267 ± 2.52914.198 ± 1.93904.009 ± 0.95264.031 ± 1.6109
SecondaryChange in Weight SDS

Change in Weight-SDS (Standard Deviation Score)

Time frame:
Day 1 to Month 6
Reported as:
Mean · Standard Deviation Score
Change in Weight SDS
Standard Deviation ScoreLUM-201 (0.8 mg/kg/Day)LUM-201 (1.6 mg/kg/Day)LUM-201 (3.2 mg/kg/Day)rhGH (34 µg/kg/Day)
Change in Weight SDS0.322 ± 0.31490.370 ± 0.28170.558 ± 0.21390.171 ± 0.1414
SecondaryChange in Weight SDS

Change in Weight-SDS (Standard Deviation Score)

Time frame:
Day 1 to Month 12
Reported as:
Mean · Standard Deviation Score
Change in Weight SDS
Standard Deviation ScoreLUM-201 (0.8 mg/kg/Day)LUM-201 (1.6 mg/kg/Day)LUM-201 (3.2 mg/kg/Day)rhGH (34 µg/kg/Day)
Change in Weight SDS0.537 ± 0.58000.446 ± 0.29120.611 ± 0.26950.392 ± 0.3261
SecondaryChange in Body Mass Index (BMI)

Change in BMI from baseline

Time frame:
Day 1 to Month 6
Reported as:
Mean · kg/m2
Change in Body Mass Index (BMI)
kg/m2LUM-201 (0.8 mg/kg/Day)LUM-201 (1.6 mg/kg/Day)LUM-201 (3.2 mg/kg/Day)rhGH (34 µg/kg/Day)
Change in Body Mass Index (BMI)0.74 ± 0.7410.80 ± 0.6430.87 ± 0.483-0.19 ± 0.623
SecondaryChange in BMI

Change in BMI (Body Mass Index) from baseline

Time frame:
Day 1 to Month 12
Reported as:
Mean · kg/m2
Change in BMI
kg/m2LUM-201 (0.8 mg/kg/Day)LUM-201 (1.6 mg/kg/Day)LUM-201 (3.2 mg/kg/Day)rhGH (34 µg/kg/Day)
Change in BMI1.12 ± 1.3050.84 ± 0.9100.95 ± 0.4800.26 ± 1.018
SecondaryChange in BMI SDS

Change in BMI SDS

Time frame:
Day 1 to Month 6
Reported as:
Mean · Standard Deviation Score
Change in BMI SDS
Standard Deviation ScoreLUM-201 (0.8 mg/kg/Day)LUM-201 (1.6 mg/kg/Day)LUM-201 (3.2 mg/kg/Day)rhGH (34 µg/kg/Day)
Change in BMI SDS0.286 ± 0.33110.318 ± 0.28520.460 ± 0.3091-0.205 ± 0.3064
SecondaryChange in BMI SDS

Change in BMI SDS This is not a Z-Score analysis. Standard deviation score of 0 is the population mean for the age/sex. Normal range is typically -2 to +2 SDS. A positive score is an improvement and a negative score a decrease.

Time frame:
Day 1 to Month 12
Reported as:
Mean · Standard Deviation Score
Change in BMI SDS
Standard Deviation ScoreLUM-201 (0.8 mg/kg/Day)LUM-201 (1.6 mg/kg/Day)LUM-201 (3.2 mg/kg/Day)rhGH (34 µg/kg/Day)
Change in BMI SDS0.317 ± 0.50170.169 ± 0.40530.411 ± 0.3097-0.075 ± 0.4969
SecondaryBone Age

Change in bone age, measured by X-ray of left hand and wrist using Greulich \& Pyle atlas

Time frame:
Day 1 to Month 6
Reported as:
Mean · Years
Bone Age
YearsLUM-201 (0.8 mg/kg/Day)LUM-201 (1.6 mg/kg/Day)LUM-201 (3.2 mg/kg/Day)rhGH (34 µg/kg):
Bone Age0.455 ± 0.20020.485 ± 0.37080.439 ± 0.21490.539 ± 0.2735
SecondaryBone Age

Change in bone age, measured by X-ray of left hand and wrist using Greulich \& Pyle atlas

Time frame:
Day 1 to Month 18
Reported as:
Mean · Years
Bone Age
YearsLUM-201 (0.8 mg/kg/Day)LUM-201 (1.6 mg/kg/Day)LUM-201 (3.2 mg/kg/Day)
Bone Age1.1515 ± 0.56471.862 ± 0.47991.585 ± 0.4960
SecondaryPharmacokinetics of LUM-201

Serum concentrations at 30 minutes (Cmax/Steady State)

Time frame:
Day 1 to Month 6
Reported as:
Mean · Concentration (ng/mL)
Pharmacokinetics of LUM-201
Concentration (ng/mL)LUM-201 (0.8 mg/kg/Day)LUM-201 (1.6 mg/kg/Day)LUM-201 (3.2 mg/kg/Day)
Day 155.2 ± 20.5154 ± 37.2186 ± 163
Month 114.2 ± 46.666.2 ± 46.3165 ± 283
Month 642.2 ± 32.471.6 ± 58.6152 ± 205
SecondaryGrowth Hormone (GH) Concentration on Maintenance Treatment

Serum GH concentration

Time frame:
Month 6
Reported as:
Mean · ng/ml
Growth Hormone (GH) Concentration on Maintenance Treatment
ng/mlLUM-201 (0.8 mg/kg/Day)LUM-201 (1.6 mg/kg/Day)LUM-201 (3.2 mg/kg/Day)rhGH (34 µg/kg/Day)
Growth Hormone (GH) Concentration on Maintenance Treatment9.16 ± 6.5017.36 ± 4.3847.51 ± 3.815—
SecondaryGrowth Hormone (GH) Concentration on Maintenance Treatment

Serum GH concentration

Time frame:
Month 12
Reported as:
Mean · ng/ml
Growth Hormone (GH) Concentration on Maintenance Treatment
ng/mlLUM-201 (0.8 mg/kg/Day)LUM-201 (1.6 mg/kg/Day)LUM-201 (3.2 mg/kg/Day)rhGH (34 µg/kg/Day)
Growth Hormone (GH) Concentration on Maintenance Treatment10.84 ± 10.8316.45 ± 5.7208.53 ± 6.339—
SecondaryInsulin-like Growth Factor 1 SDS

Serum concentrations of insulin-like growth factor 1 This is not a Z-Score analysis. Standard deviation score of 0 is the population mean for the age/sex. Normal range is typically -2 to +2 SDS. A positive score is an improvement and a negative score a decrease.

Time frame:
Month 6
Reported as:
Mean · Standard Deviation Score
Insulin-like Growth Factor 1 SDS
Standard Deviation ScoreLUM-201 (0.8 mg/kg/Day)LUM-201 (1.6 mg/kg/Day)LUM-201 (3.2 mg/kg/Day)rhGH (34 µg/kg/Day)
Insulin-like Growth Factor 1 SDS-0.296 ± 1.06770.078 ± 0.64470.116 ± 0.93180.524 ± 0.8233
SecondaryInsulin-like Growth Factor 1 SDS

Serum concentrations of insulin-like growth factor 1 This is not a Z-Score analysis. Standard deviation score of 0 is the population mean for the age/sex. Normal range is typically -2 to +2 SDS. A positive score is an improvement and a negative score a decrease.

Time frame:
Month 12
Reported as:
Mean · Standard Deviation Score
Insulin-like Growth Factor 1 SDS
Standard Deviation ScoreLUM-201 (0.8 mg/kg/Day)LUM-201 (1.6 mg/kg/Day)LUM-201 (3.2 mg/kg/Day)rhGH (34 µg/kg/Day)
Insulin-like Growth Factor 1 SDS-0.231 ± 1.1169-0.212 ± 0.70520.165 ± 1.12611.111 ± 1.1737

Adverse events

Collected over 2 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PEM Dose LUM-201 (0.8 mg/kg/Day)0/104 (0%)1/104 (1%)22/104 (21.2%)
LUM-201 (0.8 mg/kg/Day)0/18 (0%)1/18 (5.6%)14/18 (77.8%)
LUM-201 (1.6 mg/kg/Day)0/22 (0%)1/22 (4.5%)21/22 (95.5%)
LUM-201 (3.2 mg/kg/Day)0/22 (0%)0/22 (0%)20/22 (90.9%)
rhGH (34 µg/kg/Day)0/20 (0%)1/20 (5%)17/20 (85%)
Most frequent serious events
Most frequent serious events
EventPEM Dose LUM-201 (0.8 mg/kg/Day)LUM-201 (0.8 mg/kg/Day)LUM-201 (1.6 mg/kg/Day)LUM-201 (3.2 mg/kg/Day)rhGH (34 µg/kg/Day)
Cartilage development disorderMusculoskeletal and connective tissue disorders0/1041/180/220/220/20
GlycosuriaRenal and urinary disorders0/1040/180/220/221/20
Pain in extremityMusculoskeletal and connective tissue disorders0/1040/181/220/220/20
DeyhdrationMetabolism and nutrition disorders1/1040/180/220/220/20
Most frequent other events
Showing 10 of 74
Most frequent other events
EventPEM Dose LUM-201 (0.8 mg/kg/Day)LUM-201 (0.8 mg/kg/Day)LUM-201 (1.6 mg/kg/Day)LUM-201 (3.2 mg/kg/Day)rhGH (34 µg/kg/Day)
HeadacheNervous system disorders4/1045/188/226/225/20
Upper respiratory tract infectionInfections and infestations0/1041/184/227/225/20
COVID-19Infections and infestations1/1041/186/224/223/20
Viral infectionInfections and infestations0/1041/185/220/221/20
PyrexiaGastrointestinal disorders0/1043/182/225/220/20
CoughRespiratory, thoracic and mediastinal disorders2/1044/183/223/221/20
VomitingGastrointestinal disorders3/1040/182/224/224/20
ArthralgiaMusculoskeletal and connective tissue disorders1/1043/183/222/223/20
NasopharyngitisInfections and infestations0/1041/181/222/223/20
MyalgiaMusculoskeletal and connective tissue disorders0/1040/180/220/223/20

Baseline characteristics

PEM Dose LUM-201 (0.8 mg/kg/day) was not considered a dose arm as it was a qualification that needed to be met in order for subjects to enter the study.

Age, Categorical
Age, Categorical(Participants)LUM-201 (0.8 mg/kg/Day)LUM-201 (1.6 mg/kg/Day)LUM-201 (3.2 mg/kg/Day)rhGH (34 µg/kg/Day)Total
<=18 years1822222082
Between 18 and 65 years00000
>=65 years00000
Age, Continuous
Age, Continuous(months)LUM-201 (0.8 mg/kg/Day)LUM-201 (1.6 mg/kg/Day)LUM-201 (3.2 mg/kg/Day)rhGH (34 µg/kg/Day)Total
Mean101.3 ± 29.1895.2 ± 27.2694.5 ± 21.0791.4 ± 23.2695.5 ± 25.01
Sex: Female, Male
Sex: Female, Male(Participants)LUM-201 (0.8 mg/kg/Day)LUM-201 (1.6 mg/kg/Day)LUM-201 (3.2 mg/kg/Day)rhGH (34 µg/kg/Day)Total
Female71110836
Male1111121246
Race (NIH/OMB)
Race (NIH/OMB)(Participants)LUM-201 (0.8 mg/kg/Day)LUM-201 (1.6 mg/kg/Day)LUM-201 (3.2 mg/kg/Day)rhGH (34 µg/kg/Day)Total
American Indian or Alaska Native00000
Asian11114
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White1620201874
More than one race11114
Unknown or Not Reported00000
Bone Age (BA)
Bone Age (BA)(years)LUM-201 (0.8 mg/kg/Day)LUM-201 (1.6 mg/kg/Day)LUM-201 (3.2 mg/kg/Day)rhGH (34 µg/kg/Day)Total
Mean6.542 ± 2.48825.905 ± 2.38355.715 ± 1.95535.570 ± 1.97095.912 ± 2.1914
08

Study locations

43 sites
  • Center of Excellence in Diabetes and Endocrinology
    Sacramento, California 95821, United States
  • Rady Children's Hospital
    San Diego, California 92123, United States
  • Pediatric Endocrine Associates
    Greenwood Village, Colorado 80111, United States
  • Children's National Hospital
    Washington D.C., District of Columbia 20010, United States
  • Atlanta Diabetes Associates
    Atlanta, Georgia 30318, United States
  • Indiana University School of Medicine
    Indianapolis, Indiana 46202, United States
  • University of Iowa
    Iowa City, Iowa 52242, United States
  • Novak Center For Childrens Health
    Louisville, Kentucky 40202, United States
  • UMass Memorial Medical Center
    Worcester, Massachusetts 01655, United States
  • M Health, Fairview Pediatric Specialty Clinics- Discovery Clinic
    Minneapolis, Minnesota 55454, United States
  • Children's Minnesota
    Saint Paul, Minnesota 55102, United States
  • The Children's Mercy Hospital
    Kansas City, Missouri 64111, United States
  • UBMD Pediatrics
    Buffalo, New York 14203, United States
  • The Mount Sinai Hospital
    Mount Sinai, New York 30093, United States
  • NYU Grossman School of Medicine
    New York, New York 10016, United States
  • Nationwide Children's Hospital
    Columbus, Ohio 43205, United States
  • University of Oklahoma Health Sciences Center, Pediatric Diabetes and Endocrinology
    Oklahoma City, Oklahoma 73104, United States
  • Penn State College of Medicine
    Hershey, Pennsylvania 17033, United States
  • The Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Children's Hospital of Pittsburgh of UPMC
    Pittsburgh, Pennsylvania 15224, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Texas Tech University Health Sciences Center
    Amarillo, Texas 79106, United States
  • Cook Children's Medical Center
    Fort Worth, Texas 76104, United States
  • Diabetes & Glandular Disease Clinic, P.A.
    San Antonio, Texas 78229, United States
  • University of Virginia Health System
    Charlottesville, Virginia 22908, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
  • MultiCare Institute for Research and Innovation
    Tacoma, Washington 98405, United States
  • Canberra Hospital
    Garran, Australian Capital Territory 2605, Australia
  • Department of Pediatrics and Endocrinology- Monash Health
    Clayton, Victoria 3168, Australia
  • Royal Children's Hospital
    Melbourne, Victoria 3052, Australia
  • Queensland Children's Hospital
    South Brisbane, Australia
  • Schneider Children's Medical Center Institute for Endocrinology and Diabetes National Center
    Petah Tikva, Tiqwa 4920235, Israel
  • Wellington Regional Hospital CCDHB
    Newtown, Wellington Region 6021, New Zealand
  • Liggins Institute, University of Auckland
    Auckland, New Zealand
  • Klinika Pediatrii, Endokrynologii, Diabetologii z Pododdziałem Kardiologii, Uniwersytecki Dziecięcy Szpital Kliniczny im.Ludwika Zamenhofa w Białymstoku
    Bialystok, Poland
  • Klinika Endokrynologii i Chorob Metabolicznych, Instytut Centrum Zdrowia Matki Polki
    Lodz, Poland
  • Klinika Pediatrii, Diabetologii i Endokrynologii Gdansk
    Pomorskie, Poland
  • klinika Pediatrii, Endokrynologii i Diabetologii Dziecięcej
    Rzeszów, Poland
  • Sonomed - Centrum Medyczne
    Szczecin, Poland
  • Klinika Endokrynologii i Diabetologii, Instytut "Pomnik Centrum Zdrowia Dziecka
    Warsaw, Poland
  • SP Dziecięcy Szpital Kliniczny w Warszawie
    Warsaw, Poland
  • Klinika Endokrynologii i Diabetologii Wieku Rozwojowego UM
    Wroclaw, Poland
  • State Institution 'V. P. Komissarenko Institute of Endocrinology and Metabolism of the National academy of medical science of Ukraine
    Kyiv, 04114, Ukraine
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2020 to primary completion in Sep 2024, 44 months.

Results were first posted in Jun 2026, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2020
First posted
Nov 4, 2020
StartActual
Dec 31, 2020
Primary completionActual
Sep 4, 2024
CompletionActual
Sep 4, 2024
Results first posted
Jun 17, 2026
Last update
Jun 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04614337
Lead sponsor
Lumos Pharma
Responsible party
Sponsor
First posted
Nov 4, 2020
Start date
Dec 31, 2020
Primary completion
Sep 4, 2024
Completion
Sep 4, 2024
Results posted
Jun 17, 2026
Last update
Jun 17, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibutamoren

Start the discussion